{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:55:30Z","timestamp":1794477330940,"version":"4.9.1"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Arialys Therapeutics, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti-NMDA receptor (NMDAR) encephalitis is a devastating disease with severe psychiatric and neurological symptoms believed to be caused by pathogenic autoantibodies that bind to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) crosslinking adjacent NMDARs and driving their internalization. Here we describe ART5803, a humanized monovalent antibody, as a potential therapy for anti-NMDAR encephalitis. ART5803 binds with a high affinity (K\n                    <jats:sub>D<\/jats:sub>\n                    \u2009=\u20090.69\u2009nM) to GluN1-NTD without affecting NMDAR activity or inducing internalization. ART5803 blocks NMDAR internalization induced by patients\u2019 pathogenic autoantibodies, and restores NMDAR function. A marmoset animal model was developed using sustained intracerebroventricular (ICV) administration of a human pathogenic autoantibody to evoke behavioral and motor abnormalities. ART5803 ICV infusion or peripheral injections rapidly reversed these abnormalities. These data, together with the pharmacokinetic profile in cynomolgus monkeys, indicate a therapeutic potential for intravenous (IV)-administered ART5803 as a fast-acting and efficacious option for anti-NMDAR encephalitis.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-60628-1","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:02:20Z","timestamp":1750136540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Monoclonal humanized monovalent antibody blocking therapy for anti-NMDA receptor encephalitis"],"prefix":"10.1038","volume":"16","author":[{"given":"Atsuo","family":"Kanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9355-3870","authenticated-orcid":false,"given":"Takuya","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanni","family":"Yamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7190-7537","authenticated-orcid":false,"given":"Yasushi","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-4655","authenticated-orcid":false,"given":"Takuya","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Anisimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-4447","authenticated-orcid":false,"given":"Naomi","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Razai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3115-2800","authenticated-orcid":false,"given":"Akira","family":"Okimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivar","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Petshow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9099-4495","authenticated-orcid":false,"given":"Valentin","family":"Vandendoren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Bilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghiye","family":"Kazimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vallari","family":"Eastman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Snipas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5717-8634","authenticated-orcid":false,"given":"Mathew","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marty","family":"Jefson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Lichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamajuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1019-6120","authenticated-orcid":false,"given":"Hiroki","family":"Shirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3404-6640","authenticated-orcid":false,"given":"Megumi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-5215","authenticated-orcid":false,"given":"Daniel J.","family":"Hoeppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Zito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-0720","authenticated-orcid":false,"given":"Takahiro","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-2354","authenticated-orcid":false,"given":"Mitsuyuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"60628_CR1","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau, J. & Graus, F. Antibody-mediated encephalitis. N. Engl. J. Med 378, 840\u2013851 (2018).","journal-title":"N. Engl. J. Med"},{"key":"60628_CR2","first-page":"526","volume":"22","author":"J Dalmau","year":"2007","unstructured":"Dalmau, J. & Bataller, L. [Limbic encephalitis: the new cell membrane antigens and a proposal of clinical-immunological classification with therapeutic implications]. Neurologia 22, 526\u2013537 (2007).","journal-title":"Neurologia"},{"key":"60628_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.biopsych.2016.03.1046","volume":"79","author":"S Cahalan","year":"2016","unstructured":"Cahalan, S. Anti-N-Methyl-D-aspartate encephalitis: A patient\u2019s perspective. Biol. Psychiatry 79, 708\u2013709 (2016).","journal-title":"Biol. Psychiatry"},{"key":"60628_CR4","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.tins.2018.05.002","volume":"41","author":"J Jezequel","year":"2018","unstructured":"Jezequel, J., Johansson, E. M., Leboyer, M. & Groc, L. Pathogenicity of Antibodies against NMDA Receptor: Molecular insights into autoimmune psychosis. Trends Neurosci. 41, 502\u2013511 (2018).","journal-title":"Trends Neurosci."},{"key":"60628_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107426","volume":"205","author":"K Nakazawa","year":"2020","unstructured":"Nakazawa, K. & Sapkota, K. The origin of NMDA receptor hypofunction in schizophrenia. Pharm. Ther. 205, 107426 (2020).","journal-title":"Pharm. Ther."},{"key":"60628_CR6","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","volume":"18","author":"J Dalmau","year":"2019","unstructured":"Dalmau, J. et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 18, 1045\u20131057 (2019).","journal-title":"Lancet Neurol."},{"key":"60628_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer, M. J. et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12, 157\u2013165 (2013).","journal-title":"Lancet Neurol."},{"key":"60628_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e36042","volume":"10","author":"W Banach","year":"2024","unstructured":"Banach, W. et al. Ovarian teratoma-associated Anti-NMDAR encephalitis in women with first-time neuropsychiatric symptoms: A meta-analysis and systematic review of reported cases. Heliyon 10, e36042 (2024).","journal-title":"Heliyon"},{"key":"60628_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.105161","volume":"147","author":"D Hunter","year":"2021","unstructured":"Hunter, D., Jamet, Z. & Groc, L. Autoimmunity and NMDA receptor in brain disorders: Where do we stand?. Neurobiol. Dis. 147, 105161 (2021).","journal-title":"Neurobiol. Dis."},{"key":"60628_CR10","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","volume":"21","author":"H Pruss","year":"2021","unstructured":"Pruss, H. Autoantibodies in neurological disease. Nat. Rev. Immunol. 21, 798\u2013813 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"60628_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/ana.24195","volume":"76","author":"EH Moscato","year":"2014","unstructured":"Moscato, E. H. et al. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann. Neurol. 76, 108\u2013119 (2014).","journal-title":"Ann. Neurol."},{"key":"60628_CR12","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","volume":"30","author":"EG Hughes","year":"2010","unstructured":"Hughes, E. G. et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J. Neurosci. 30, 5866\u20135875 (2010).","journal-title":"J. Neurosci."},{"key":"60628_CR13","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1093\/brain\/aww208","volume":"139","author":"J Kreye","year":"2016","unstructured":"Kreye, J. et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain 139, 2641\u20132652 (2016).","journal-title":"Brain"},{"key":"60628_CR14","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s00415-018-9042-1","volume":"265","author":"LT Ly","year":"2018","unstructured":"Ly, L. T. et al. Affinities of human NMDA receptor autoantibodies: implications for disease mechanisms and clinical diagnostics. J. Neurol. 265, 2625\u20132632 (2018).","journal-title":"J. Neurol."},{"key":"60628_CR15","doi-asserted-by":"publisher","first-page":"11082","DOI":"10.1523\/JNEUROSCI.0064-12.2012","volume":"32","author":"AJ Gleichman","year":"2012","unstructured":"Gleichman, A. J., Spruce, L. A., Dalmau, J., Seeholzer, S. H. & Lynch, D. R. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J. Neurosci. 32, 11082\u201311094 (2012).","journal-title":"J. Neurosci."},{"key":"60628_CR16","first-page":"3969","volume":"46","author":"DG Covell","year":"1986","unstructured":"Covell, D. G. et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab\u2019)2, and Fab\u2019 in mice. Cancer Res. 46, 3969\u20133978 (1986).","journal-title":"Cancer Res."},{"key":"60628_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7007-10-80","volume":"10","author":"N Kurosawa","year":"2012","unstructured":"Kurosawa, N., Yoshioka, M., Fujimoto, R., Yamagishi, F. & Isobe, M. Rapid production of antigen-specific monoclonal antibodies from a variety of animals. BMC Biol. 10, 80 (2012).","journal-title":"BMC Biol."},{"key":"60628_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-11-39","volume":"11","author":"N Kurosawa","year":"2011","unstructured":"Kurosawa, N., Yoshioka, M. & Isobe, M. Target-selective homologous recombination cloning for high-throughput generation of monoclonal antibodies from single plasma cells. BMC Biotechnol. 11, 39 (2011).","journal-title":"BMC Biotechnol."},{"key":"60628_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677\u2013681 (1998).","journal-title":"Nat. Biotechnol."},{"key":"60628_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/protein\/gzw040","volume":"29","author":"T Schlothauer","year":"2016","unstructured":"Schlothauer, T. et al. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng. Des. Sel. 29, 457\u2013466 (2016).","journal-title":"Protein Eng. Des. Sel."},{"key":"60628_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2362789","volume":"16","author":"WK Tsai","year":"2024","unstructured":"Tsai, W. K. et al. Nonclinical immunogenicity risk assessment for knobs-into-holes bispecific IgG(1) antibodies. MAbs 16, 2362789 (2024).","journal-title":"MAbs"},{"key":"60628_CR22","doi-asserted-by":"publisher","unstructured":"Abdeldaim, D. T. & Schindowski, K. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics 15, https:\/\/doi.org\/10.3390\/pharmaceutics15102402 (2023).","DOI":"10.3390\/pharmaceutics15102402"},{"key":"60628_CR23","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1523\/JNEUROSCI.6041-10.2011","volume":"31","author":"AN Farina","year":"2011","unstructured":"Farina, A. N. et al. Separation of domain contacts is required for heterotetrameric assembly of functional NMDA receptors. J. Neurosci. 31, 3565\u20133579 (2011).","journal-title":"J. Neurosci."},{"key":"60628_CR24","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1021\/acschembio.9b00016","volume":"14","author":"JC Stuber","year":"2019","unstructured":"Stuber, J. C., Kast, F. & Pluckthun, A. High-throughput quantification of surface protein internalization and degradation. ACS Chem. Biol. 14, 1154\u20131163 (2019).","journal-title":"ACS Chem. Biol."},{"key":"60628_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fnmol.2018.00154","volume":"11","author":"U Breitinger","year":"2018","unstructured":"Breitinger, U. et al. PKA and PKC Modulators affect ion channel function and internalization of recombinant Alpha1 and Alpha1-beta glycine receptors. Front Mol. Neurosci. 11, 154 (2018).","journal-title":"Front Mol. Neurosci."},{"key":"60628_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11947-x","volume":"7","author":"H Guo","year":"2017","unstructured":"Guo, H. et al. A NMDA-receptor calcium influx assay sensitive to stimulation by glutamate and glycine\/D-serine. Sci. Rep. 7, 11608 (2017).","journal-title":"Sci. Rep."},{"key":"60628_CR27","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1523\/JNEUROSCI.3918-05.2006","volume":"26","author":"CD Kopec","year":"2006","unstructured":"Kopec, C. D., Li, B., Wei, W., Boehm, J. & Malinow, R. Glutamate receptor exocytosis and spine enlargement during chemically induced long-term potentiation. J. Neurosci. 26, 2000\u20132009 (2006).","journal-title":"J. Neurosci."},{"key":"60628_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/28190","volume":"394","author":"G Miesenbock","year":"1998","unstructured":"Miesenbock, G., De Angelis, D. A. & Rothman, J. E. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394, 192\u2013195 (1998).","journal-title":"Nature"},{"key":"60628_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.bbr.2008.06.035","volume":"194","author":"T Mihara","year":"2008","unstructured":"Mihara, T., Iwashita, A. & Matsuoka, N. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson\u2019s disease drugs. Behav. Brain Res. 194, 152\u2013161 (2008).","journal-title":"Behav. Brain Res."},{"key":"60628_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12987-018-0093-6","volume":"15","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration. Fluids Barriers CNS 15, 10 (2018).","journal-title":"Fluids Barriers CNS"},{"key":"60628_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaneurol.2022.4352","volume":"80","author":"M Galovic","year":"2023","unstructured":"Galovic, M. et al. In Vivo N-Methyl-d-Aspartate Receptor (NMDAR) density as assessed using positron emission tomography during recovery from nmdar-antibody encephalitis. JAMA Neurol. 80, 211\u2013213 (2023).","journal-title":"JAMA Neurol."},{"key":"60628_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04439-7","volume":"9","author":"S Incontro","year":"2018","unstructured":"Incontro, S. et al. The CaMKII\/NMDA receptor complex controls hippocampal synaptic transmission by kinase-dependent and independent mechanisms. Nat. Commun. 9, 2069 (2018).","journal-title":"Nat. Commun."},{"key":"60628_CR33","doi-asserted-by":"publisher","first-page":"e0256972","DOI":"10.1371\/journal.pone.0256972","volume":"16","author":"W Yue","year":"2021","unstructured":"Yue, W., Caldwell, S., Risbrough, V., Powell, S. & Zhou, X. Chronic presence of blood circulating anti-NMDAR1 autoantibodies impairs cognitive function in mice. PLoS One 16, e0256972 (2021).","journal-title":"PLoS One"},{"key":"60628_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"60628_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neuroscience.2020.01.006","volume":"429","author":"NJ Morriss","year":"2020","unstructured":"Morriss, N. J. et al. Automated quantification of immunohistochemical staining of large animal brain tissue using QuPath software. Neuroscience 429, 235\u2013244 (2020).","journal-title":"Neuroscience"},{"key":"60628_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113166","volume":"42","author":"M Ceanga","year":"2023","unstructured":"Ceanga, M. et al. Human NMDAR autoantibodies disrupt excitatory-inhibitory balance, leading to hippocampal network hypersynchrony. Cell Rep. 42, 113166 (2023).","journal-title":"Cell Rep."},{"key":"60628_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2215-0366(16)30375-3","volume":"4","author":"BR Lennox","year":"2017","unstructured":"Lennox, B. R. et al. Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study. Lancet Psychiatry 4, 42\u201348 (2017).","journal-title":"Lancet Psychiatry"},{"key":"60628_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01700-3","volume":"8","author":"J Jezequel","year":"2017","unstructured":"Jezequel, J. et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nat. Commun. 8, 1791 (2017).","journal-title":"Nat. Commun."},{"key":"60628_CR39","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1007\/s00415-017-8582-0","volume":"264","author":"C Finke","year":"2017","unstructured":"Finke, C., Bartels, F., Lutt, A., Pruss, H. & Harms, L. High prevalence of neuronal surface autoantibodies associated with cognitive deficits in cancer patients. J. Neurol. 264, 1968\u20131977 (2017).","journal-title":"J. Neurol."},{"key":"60628_CR40","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/acn3.120","volume":"1","author":"S Doss","year":"2014","unstructured":"Doss, S. et al. High prevalence of NMDA receptor IgA\/IgM antibodies in different dementia types. Ann. Clin. Transl. Neurol. 1, 822\u2013832 (2014).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"60628_CR41","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/s41380-020-0672-1","volume":"26","author":"H Pan","year":"2021","unstructured":"Pan, H. et al. Multiple inducers and novel roles of autoantibodies against the obligatory NMDAR subunit NR1: a translational study from chronic life stress to brain injury. Mol. Psychiatry 26, 2471\u20132482 (2021).","journal-title":"Mol. Psychiatry"},{"key":"60628_CR42","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/ana.25460","volume":"85","author":"NK Wenke","year":"2019","unstructured":"Wenke, N. K. et al. N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit. Ann. Neurol. 85, 771\u2013776 (2019).","journal-title":"Ann. Neurol."},{"key":"60628_CR43","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fpsyt.2017.00037","volume":"8","author":"G Lucchese","year":"2017","unstructured":"Lucchese, G. From toxoplasmosis to schizophrenia via NMDA dysfunction: Peptide overlap between toxoplasma gondii and N-methyl-d-aspartate receptors as a potential mechanistic link. Front Psychiatry 8, 37 (2017).","journal-title":"Front Psychiatry"},{"key":"60628_CR44","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.3201\/eid0911.030143","volume":"9","author":"EF Torrey","year":"2003","unstructured":"Torrey, E. F. & Yolken, R. H. Toxoplasma gondii and schizophrenia. Emerg. Infect. Dis. 9, 1375\u20131380 (2003).","journal-title":"Emerg. Infect. Dis."},{"key":"60628_CR45","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1176\/appi.ajp.2011.11030516","volume":"168","author":"ME Benros","year":"2011","unstructured":"Benros, M. E. et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am. J. Psychiatry 168, 1303\u20131310 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"60628_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"60628_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/srep12805","volume":"5","author":"H Pruss","year":"2015","unstructured":"Pruss, H. et al. Anti-NMDA receptor encephalitis in the polar bear (Ursus maritimus) Knut. Sci. Rep. 5, 12805 (2015).","journal-title":"Sci. Rep."},{"key":"60628_CR48","doi-asserted-by":"publisher","unstructured":"Kita, Y. et al. Cellular-resolution gene expression profiling in the neonatal marmoset brain reveals dynamic species- and region-specific differences. Proc. Natl Acad. Sci. USA 118, https:\/\/doi.org\/10.1073\/pnas.2020125118 (2021).","DOI":"10.1073\/pnas.2020125118"},{"key":"60628_CR49","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/epi.14662","volume":"60","author":"O Taraschenko","year":"2019","unstructured":"Taraschenko, O. et al. A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis. Epilepsia 60, 452\u2013463 (2019).","journal-title":"Epilepsia"},{"key":"60628_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/brain\/awu310","volume":"138","author":"J Planaguma","year":"2015","unstructured":"Planaguma, J. et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain 138, 94\u2013109 (2015).","journal-title":"Brain"},{"key":"60628_CR51","doi-asserted-by":"publisher","unstructured":"Jones, B. E. et al. Autoimmune receptor encephalitis in mice induced by active immunization with conformationally stabilized holoreceptors. Sci. Transl Med. 11, https:\/\/doi.org\/10.1126\/scitranslmed.aaw0044 (2019).","DOI":"10.1126\/scitranslmed.aaw0044"},{"key":"60628_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2019.112153","volume":"376","author":"AJ Polis","year":"2019","unstructured":"Polis, A. J., Fitzgerald, P. J., Hale, P. J. & Watson, B. O. Rodent ketamine depression-related research: Finding patterns in a literature of variability. Behav. Brain Res. 376, 112153 (2019).","journal-title":"Behav. Brain Res."},{"key":"60628_CR53","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1258\/002367781780959107","volume":"15","author":"CJ Green","year":"1981","unstructured":"Green, C. J., Knight, J., Precious, S. & Simpkin, S. Ketamine alone and combined with diazepam or xylazine in laboratory animals: a 10 year experience. Lab Anim. 15, 163\u2013170 (1981).","journal-title":"Lab Anim."},{"key":"60628_CR54","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41594-024-01387-3","volume":"31","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. Structural basis for antibody-mediated NMDA receptor clustering and endocytosis in autoimmune encephalitis. Nat. Struct. Mol. Biol. 31, 1987\u20131996 (2024).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"60628_CR55","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1038\/s41594-024-01386-4","volume":"31","author":"K Michalski","year":"2024","unstructured":"Michalski, K. et al. Structural and functional mechanisms of anti-NMDAR autoimmune encephalitis. Nat. Struct. Mol. Biol. 31, 1975\u20131986 (2024).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"60628_CR56","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1093\/brain\/awae163","volume":"147","author":"Z Jamet","year":"2024","unstructured":"Jamet, Z. et al. NMDA receptor autoantibodies primarily impair the extrasynaptic compartment. Brain 147, 2745\u20132760 (2024).","journal-title":"Brain"},{"key":"60628_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-08695-3","volume":"7","author":"L Mikasova","year":"2017","unstructured":"Mikasova, L. et al. Stress hormone rapidly tunes synaptic NMDA receptor through membrane dynamics and mineralocorticoid signalling. Sci. Rep. 7, 8053 (2017).","journal-title":"Sci. Rep."},{"key":"60628_CR58","doi-asserted-by":"publisher","unstructured":"Bueschke, N., Amaral-Silva, L., Hu, M., Alvarez, A. & Santin, J. M. Plasticity in the Functional Properties of NMDA Receptors Improves Network Stability during Severe Energy Stress. J Neurosci 44, https:\/\/doi.org\/10.1523\/JNEUROSCI.0502-23.2024 (2024).","DOI":"10.1523\/JNEUROSCI.0502-23.2024"},{"key":"60628_CR59","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13024-023-00637-0","volume":"18","author":"VK Ramanan","year":"2023","unstructured":"Ramanan, V. K. & Day, G. S. Anti-amyloid therapies for Alzheimer disease: finally, good news for patients. Mol. Neurodegener. 18, 42 (2023).","journal-title":"Mol. Neurodegener."},{"key":"60628_CR60","doi-asserted-by":"publisher","first-page":"414","DOI":"10.14283\/jpad.2021.56","volume":"8","author":"SL Lowe","year":"2021","unstructured":"Lowe, S. L. et al. Donanemab (LY3002813) Phase 1b study in alzheimer\u2019s disease: Rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J. Prev. Alzheimers Dis. 8, 414\u2013424 (2021).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"60628_CR61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/psp4.12538","volume":"9","author":"M Kuchimanchi","year":"2020","unstructured":"Kuchimanchi, M., Monine, M., Kandadi Muralidharan, K., Woodward, C. & Penner, N. Phase II dose selection for alpha synuclein-targeting antibody cinpanemab (BIIB054) based on target protein binding levels in the brain. CPT Pharmacomet. Syst. Pharm. 9, 515\u2013522 (2020).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"60628_CR62","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with parkinson disease: A randomized clinical trial. JAMA Neurol. 75, 1206\u20131214 (2018).","journal-title":"JAMA Neurol."},{"key":"60628_CR63","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1021\/acs.analchem.9b01325","volume":"91","author":"TS Hageman","year":"2019","unstructured":"Hageman, T. S. & Weis, D. D. Reliable identification of significant differences in differential hydrogen exchange-mass spectrometry measurements using a hybrid significance testing approach. Anal. Chem. 91, 8008\u20138016 (2019).","journal-title":"Anal. Chem."},{"key":"60628_CR64","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0165-0270(91)90128-M","volume":"37","author":"L Stoppini","year":"1991","unstructured":"Stoppini, L., Buchs, P. A. & Muller, D. A simple method for organotypic cultures of nervous tissue. J. Neurosci. Methods 37, 173\u2013182 (1991).","journal-title":"J. Neurosci. Methods"},{"key":"60628_CR65","doi-asserted-by":"publisher","unstructured":"Woods, G. & Zito, K. Preparation of gene gun bullets and biolistic transfection of neurons in slice culture. J Vis Exp https:\/\/doi.org\/10.3791\/675 (2008).","DOI":"10.3791\/675"},{"key":"60628_CR66","doi-asserted-by":"publisher","first-page":"12129","DOI":"10.1523\/JNEUROSCI.6662-10.2011","volume":"31","author":"GF Woods","year":"2011","unstructured":"Woods, G. F., Oh, W. C., Boudewyn, L. C., Mikula, S. K. & Zito, K. Loss of PSD-95 enrichment is not a prerequisite for spine retraction. J. Neurosci. 31, 12129\u201312138 (2011).","journal-title":"J. Neurosci."},{"key":"60628_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/1475-925X-2-13","volume":"2","author":"TA Pologruto","year":"2003","unstructured":"Pologruto, T. A., Sabatini, B. L. & Svoboda, K. ScanImage: flexible software for operating laser scanning microscopes. Biomed. Eng. Online 2, 13 (2003).","journal-title":"Biomed. Eng. Online"},{"key":"60628_CR68","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ab.2019.03.010","volume":"575","author":"H Sander","year":"2019","unstructured":"Sander, H., Wallace, S., Plouse, R., Tiwari, S. & Gomes, A. V. Ponceau S waste: Ponceau S staining for total protein normalization. Anal. Biochem 575, 44\u201353 (2019).","journal-title":"Anal. Biochem"},{"key":"60628_CR69","unstructured":"Yamaki, S. https:\/\/BioRender.com\/c06a44s (2025)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60628-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60628-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T05:02:22Z","timestamp":1750136542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60628-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60628"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60628-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K., M.Maeda, S.K., and S.B. are consultants, and S.Y., A.R., R.K., V.E., S.J.S., M.Mitchell, M.Maurer, M.J., J.L., P.F., and M.Matsumoto are full-time employees of Arialys Therapeutics., Inc. A.K., T.K., M.Maeda, Y.A., T.Shimomura, T.M., K.K., T.Shimada, K.N., N.N., Y.K., A.S., D.Y., M.Adachi, and D.J.H. are full-time employees of Astellas Pharma Inc. K.S., A.O., H.S., and M.Matsumoto were full-time employees of Astellas Pharma Inc. at the time the part of research was conducted, but are no longer affiliated with the company. V.V. and S.B. are full-time employees of Vanadro, LLC. K.Z. and T.I. received grant support from Astellas Pharma, Inc. The remaining authors declare no competing interests. ART5803 was originally developed by Astellas Pharma, Inc. ART5803 was subsequently acquired from Astellas by Arialys Therapeutics, Inc. via the execution of an exclusive worldwide licensing agreement. Arialys further developed the asset, including work within this manuscript, and is now conducting clinical studies. The work described in this manuscript was therefore conducted under the control of either Astellas or Arialys.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5292"}}